Nachrichten zur Regenxbio Inc. Aktie

REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript

…

Hunter Syndrome Market to Register Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - Denali Therapeutics Inc., JCR Pharmaceuticals Co., Ltd., REGENXBIO Inc., Shire, Takeda

The dynamics of the Hunter syndrome market are anticipated to change in the coming years owing to the launch of…

REGENXBIO Inc. (RGNX) Q3 2023 Earnings Call Transcript

…

Form 8-K REGENXBIO Inc. For: Aug 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights

Continued progress on 5x25 strategy to advance five AAV Therapeutics from REGENXBIOs internal pipeline and licensed programs into pivotal-stage or…

Earnings Preview: Regenxbio

REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., July 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call…

5 Analysts Have This to Say About Regenxbio

Latest Ratings for RGNX DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsMarket Perform Feb 2022SVB LeerinkMaintainsMarket Perform Jan 2022SVB LeerinkMaintainsMarket Perform …

Regenxbio, UPenn file second patent suit against Sarepta over DMD therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K REGENXBIO Inc. For: Jun 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

The Latest Analyst Ratings for Regenxbio

Latest Ratings for RGNX DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsMarket Perform Feb 2022SVB LeerinkMaintainsMarket Perform Jan 2022SVB LeerinkMaintainsMarket Perform …

Regenxbio could be a gene therapy pioneer with multiple ways to ...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference

ROCKVILLE, Md., June 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present and host one-on-one…

REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights

Continued progress on 5x25 strategy to advance five AAV Therapeutics from REGENXBIOs internal pipeline and licensed programs into pivotal-stage or…

REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., April 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call…

Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?

The company focuses on using its technology for gene-editing therapies....…

Regenxbio stock pops on FDA fast track tag for Duchenne gene therapy RGX-202

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

RegenxBio Gets FDA Fast-Track Designation for RGX-202 to Treat Duchenne Muscular Dystrophy

RegenxBio Gets FDA Fast-Track Designation for RGX-202 to Treat Duchenne Muscular Dystrophy...…

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., March 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming…

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of 6.76% and 12.21%, respectively, for the quarter ended December 2022. Do the…

REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights

Continued progress on 5x25 strategy to advance five AAV Therapeutics from REGENXBIOs internal pipeline and licensed programs into pivotal-stage or…

Regenxbio touts interim results from trial of pediatric rare disease gene therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., Feb. 21, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call…

REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023

New interim data from Phase I/I/III trial of RGX-121 for the treatment of MPS II and Phase I/II trial of…

REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

RGX-314 produced by the NAVXpress platform process has been well-tolerated and demonstrated a similar clinical profile to the initial adherent…

REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference

ROCKVILLE, Md., Feb. 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the SVB…

REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference

ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three presentations on RGX-314 will be…

Regenxbio begins phase 1/2 trial of Duchenne muscular dystrophy candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients

- Company has initiated Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 - Company also enrolling newly active observational screening study,…

Regenxbio names Curran Simpson as COO

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS

Curran Simpson has been appointed Chief Operating Officer Shiva Fritsch assumes the role of Chief Communications Officer ROCKVILLE, Md., Jan.…

Insiderhandel: Chief Medical Officer verkauft Aktien von Regenxbio im Wert von 69.559$

Pakola, Steve - Vorstand - Tag der Transaktion: 2023-01-03...…

REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the 41st…

REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease

RGX-181 and RGX-381 are potential one-time AAV Therapeutics for the treatment of the CNS and ocular manifestations of CLN2 disease,…

REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I

RGX-111 is an investigational AAV Therapeutic for the treatment of severe MPS I that is part of REGENXBIOs clinical-stage pipeline…

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Nov. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming…

Regenxbio slumps 17% as Q3 Zolgensma royalty revenue falls, net loss widens

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -12.90% and 10.95%, respectively, for the quarter ended September 2022. Do the…

Form 10-Q REGENXBIO Inc. For: Sep 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K REGENXBIO Inc. For: Nov 03

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

Continued progress on 5x25 strategy to advance five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or…

REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

RGX-314 continues to be well tolerated in 50 patients from Cohorts 1-3 with no drug-related serious adverse events Patients treated…

dpa-AFX ProFeed